Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: a network meta‐analysis of …
OS Alkhezi, AA Alahmed, OM Alfayez… - Obesity …, 2023 - Wiley Online Library
Tirzepatide is a new glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) that has shown
promising results for weight loss. A Bayesian network meta‐analysis was conducted to …
promising results for weight loss. A Bayesian network meta‐analysis was conducted to …
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled …
X Gao, X Hua, X Wang, W Xu, Y Zhang… - Frontiers in …, 2022 - frontiersin.org
Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …
conventional anti-obesity drug systematically in obese or overweight patients without …
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight …
ER Hankosky, H Wang, LM Neff, H Kan… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aim To assess the effect of tirzepatide on long‐term risk of atherosclerotic cardiovascular
disease (ASCVD) among people with obesity or overweight without diabetes from …
disease (ASCVD) among people with obesity or overweight without diabetes from …
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
AJ Scheen - Annales d'Endocrinologie, 2023 - Elsevier
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged
place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic …
place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic …
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
ED Michos, F Lopez‐Jimenez… - Journal of the American …, 2023 - Am Heart Assoc
Obesity remains a major public health problem, affecting almost half of adults in the United
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT‐1 trial
ER Hankosky, H Wang, LM Neff, H Kan… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim We assessed the impact of tirzepatide on 10‐year predicted risk of developing type 2
diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this …
diabetes (T2D) among participants in the SURMOUNT‐1 trial. Materials and Methods In this …
Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials
Background and aims This study aims to explore the efficacy and safety of tirzepatide for
patients with type 2 diabetes (T2D). Methods Using specific keywords, we comprehensively …
patients with type 2 diabetes (T2D). Methods Using specific keywords, we comprehensively …
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic …
P Karakasis, D Patoulias, K Pamporis, P Stachteas… - Metabolism, 2023 - Elsevier
Aims The present systematic review aimed to synthesize available data from recently
published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally …
published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally …
GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and
others) now promises effective, non-invasive treatment of obesity for individuals with and …
others) now promises effective, non-invasive treatment of obesity for individuals with and …
Intranasal oxytocin for obesity
F Plessow, L Kerem, ML Wronski, E Asanza… - NEJM …, 2024 - evidence.nejm.org
Background Accumulating preclinical and preliminary translational evidence shows that the
hypothalamic peptide oxytocin reduces food intake, increases energy expenditure, and …
hypothalamic peptide oxytocin reduces food intake, increases energy expenditure, and …